Edgewise Advances EDG-7500 for Hypertrophic Cardiomyopathy
Boulder, Colorado, U.S., September 22, 2026 Edgewise Therapeutics, Inc. has unveiled new preclinical pharmacology findings describing the differentiated mechanism...
cardiovascular drugs
Advertisement
Milestone Pharmaceuticals Secures First Overseas Etripamil Approval
Montreal, Quebec, and Charlotte, North Carolina — September 3, 2026 Milestone Pharmaceuticals announced that China’s National Medical Products Administration...
Atrium Therapeutics Earns $15M Milestone from Bristol Myers Squibb
San Diego, California, USA – April 23, 2026 Atrium Therapeutics announced it has achieved a $15 million development milestone...
Amlodipine Recall Issued Over Wrong Drug Risk
Ottawa, Canada — February 6, 2026 Health authorities have issued a public advisory announcing the recall of two lots...
Asundexian Shows 26% Stroke Risk Reduction in Phase III
Dateline – New Orleans, USA, Feb. 5, 2026 — Bayer announced that its investigational oral Factor XIa inhibitor asundexian...
Advertisements
NMPA Approves MYQORZO in China for Obstructive HCM
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 — Cytokinetics, Incorporated (NASDAQ: CYTK) announced that MYQORZO® (aficamten) has received approval...
Advertisement
